Hologic, Inc. (HOLX) Rating Reiterated by Barclays PLC

Barclays PLC reiterated their overweight rating on shares of Hologic, Inc. (NASDAQ:HOLX) in a research report released on Monday, July 17th. The firm currently has a $53.00 target price on the medical equipment provider’s stock, up from their prior target price of $50.00.

Other equities research analysts also recently issued research reports about the stock. Piper Jaffray Companies restated a buy rating and issued a $51.00 price objective on shares of Hologic in a research note on Friday, July 14th. Stifel Nicolaus reiterated a buy rating on shares of Hologic in a research note on Friday, July 14th. BTIG Research reiterated a buy rating and set a $47.00 price target on shares of Hologic in a research note on Sunday, May 14th. Canaccord Genuity reiterated a buy rating and set a $53.00 price target on shares of Hologic in a research note on Tuesday, May 9th. Finally, Needham & Company LLC lifted their price target on shares of Hologic from $46.00 to $50.00 and gave the stock a buy rating in a research note on Tuesday, April 4th. Five analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Hologic presently has a consensus rating of Buy and an average price target of $48.64.

Hologic (NASDAQ:HOLX) traded down 1.65% on Monday, reaching $39.25. 5,768,147 shares of the company’s stock were exchanged. Hologic has a 12 month low of $35.15 and a 12 month high of $46.80. The firm has a 50 day moving average of $45.06 and a 200 day moving average of $42.98. The stock has a market capitalization of $11.01 billion, a PE ratio of 14.62 and a beta of 0.90.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.49 by $0.01. The business had revenue of $806.10 million for the quarter, compared to the consensus estimate of $799.70 million. Hologic had a net margin of 25.65% and a return on equity of 23.18%. Hologic’s quarterly revenue was up 12.4% on a year-over-year basis. During the same quarter last year, the company posted $0.51 earnings per share. Equities analysts predict that Hologic will post $2.01 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was first reported by [[site]] and is owned by of [[site]]. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at [[permalink]].

In other news, Director Lawrence M. Levy sold 9,076 shares of the business’s stock in a transaction on Wednesday, May 17th. The shares were sold at an average price of $42.80, for a total value of $388,452.80. Following the sale, the director now owns 43,165 shares in the company, valued at approximately $1,847,462. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Lawrence M. Levy sold 9,837 shares of the business’s stock in a transaction on Wednesday, May 10th. The shares were sold at an average price of $45.34, for a total transaction of $446,009.58. Following the completion of the sale, the director now owns 40,577 shares in the company, valued at approximately $1,839,761.18. The disclosure for this sale can be found here. Insiders sold a total of 63,562 shares of company stock worth $2,802,013 in the last 90 days. 0.79% of the stock is owned by corporate insiders.

Several large investors have recently modified their holdings of the stock. TrimTabs Asset Management LLC boosted its position in Hologic by 88.8% in the first quarter. TrimTabs Asset Management LLC now owns 2,993 shares of the medical equipment provider’s stock worth $127,000 after buying an additional 1,408 shares in the last quarter. Beck Mack & Oliver LLC acquired a new position in Hologic during the second quarter worth about $209,000. Notis McConarty Edward acquired a new position in Hologic during the second quarter worth about $213,000. Advisor Partners LLC acquired a new position in Hologic during the first quarter worth about $201,000. Finally, CAPROCK Group Inc. acquired a new position in Hologic during the second quarter worth about $214,000. Institutional investors own 94.32% of the company’s stock.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.